Compare Aehr Test Systems (AEHR) vs Moderna, Inc. (MRNA) Price & Performance

AEHR Test Systems (AEHR) surged 25.02% to $132.77, driven by strong earnings beats and a $22 million follow-on order for AI processor wafer-level burn-in systems (Accesswire, August 12, 2026). The stock exhibits bullish technical signals with support at $112 and resistance at $129, though RSI suggests overbought conditions. Revenue reached $58.97 million in 2025, but net income remained negative at -$3.91 million, reflecting high growth investments.

Outlook is optimistic due to AI and silicon photonics demand, with FY27 revenue growth projected at 160–200% (Seeking Alpha, July 18, 2026). Risks include customer concentration and negative cash flow. Analysts are mixed (33% buy, 67% hold), highlighting valuation concerns at a P/S of 71.87. Upside potential exists if execution aligns with backlog growth.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.